Villar-Menéndez et al., 2013 - Google Patents
Increased 5-methylcytosine and decreased 5-hydroxymethylcytosine levels are associated with reduced striatal A2AR levels in Huntington's diseaseVillar-Menéndez et al., 2013
View PDF- Document ID
- 4828941929919670758
- Author
- Villar-Menéndez I
- Blanch M
- Tyebji S
- Pereira-Veiga T
- Albasanz J
- Martín M
- Ferrer I
- Pérez-Navarro E
- Barrachina M
- Publication year
- Publication venue
- Neuromolecular medicine
External Links
Snippet
Abstract Adenosine A2A receptor (A2AR) is a G-protein-coupled receptor highly expressed in basal ganglia. Its expression levels are severely reduced in Huntington's disease (HD), and several pharmacological therapies have shown its implication in this neurodegenerative …
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES OR MICRO-ORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or micro-organisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or micro-organisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Hybridisation probes
- C12Q1/6883—Hybridisation probes for diseases caused by alterations of genetic material
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES OR MICRO-ORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives, e.g. steroids
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
- G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES OR MICRO-ORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Villar-Menéndez et al. | Increased 5-methylcytosine and decreased 5-hydroxymethylcytosine levels are associated with reduced striatal A2AR levels in Huntington’s disease | |
| Han et al. | Microglial PGC-1α protects against ischemic brain injury by suppressing neuroinflammation | |
| Shi et al. | Stroke subtype-dependent synapse elimination by reactive gliosis in mice | |
| Pensalfini et al. | Endosomal dysfunction induced by directly overactivating Rab5 recapitulates prodromal and neurodegenerative features of Alzheimer’s disease | |
| Gerbino et al. | The loss of TBK1 kinase activity in motor neurons or in all cell types differentially impacts ALS disease progression in SOD1 mice | |
| Kurz et al. | A53T-alpha-synuclein overexpression impairs dopamine signaling and striatal synaptic plasticity in old mice | |
| Zachariah et al. | Linking epigenetics to human disease and Rett syndrome: the emerging novel and challenging concepts in MeCP2 research | |
| Song et al. | Schizophrenia-like features in transgenic mice overexpressing human HO-1 in the astrocytic compartment | |
| Su et al. | PGC− 1α promoter methylation in Parkinson’s disease | |
| Araujo et al. | FoxP1 orchestration of ASD-relevant signaling pathways in the striatum | |
| Bender et al. | TOM40 mediates mitochondrial dysfunction induced by α-synuclein accumulation in Parkinson’s disease | |
| Liu et al. | Neuron-specific antioxidant OXR1 extends survival of a mouse model of amyotrophic lateral sclerosis | |
| Hamilton et al. | Stearoyl-CoA Desaturase inhibition reverses immune, synaptic and cognitive impairments in an Alzheimer’s disease mouse model | |
| Gideons et al. | Chronic lithium treatment elicits its antimanic effects via BDNF-TrkB dependent synaptic downscaling | |
| Tränkner et al. | A microglia sublineage protects from sex-linked anxiety symptoms and obsessive compulsion | |
| Sepe et al. | Nucleotide excision repair in chronic neurodegenerative diseases | |
| Chen et al. | Glucocorticoid-dependent hippocampal transcriptome in male rats: pathway-specific alterations with aging | |
| US20230029577A1 (en) | Compositions for restoring gene expression in neuropsychiatric or neurodegenerative disorders | |
| Li et al. | Aberrant palmitoylation caused by a ZDHHC21 mutation contributes to pathophysiology of Alzheimer’s disease | |
| Poot | Towards identification of individual etiologies by resolving genomic and biological conundrums in patients with autism spectrum disorders | |
| JP2022510341A (en) | How to detect, prevent, recover and treat neurological disorders | |
| Sanjuan-Ruiz et al. | Wild-type FUS corrects ALS-like disease induced by cytoplasmic mutant FUS through autoregulation | |
| Boni et al. | DNA methylation: A mechanism for sustained alteration of KIR4. 1 expression following central nervous system insult | |
| Rayaprolu et al. | Partial loss of ATP13A2 causes selective gliosis independent of robust lipofuscinosis | |
| Valsecchi et al. | The transcription factor Nurr1 is upregulated in amyotrophic lateral sclerosis patients and SOD1-G93A mice |